Aldeyra Therapeutics to Participate in the Jefferies London Healthcare Conference

Rhea-AI Summary

Aldeyra Therapeutics (ALDX), a biotech company focused on immune-mediated and metabolic diseases, has announced its participation in the Jefferies London Healthcare Conference 2024. President and CEO Todd C. Brady will engage in a fireside chat with Jefferies' Senior VP of Biotechnology Equity Research, Kelly Shi, on November 21, 2024, at 12:30 p.m. GMT. The conference runs from November 19-21, 2024, in London. A live webcast will be available on Aldeyra's investor relations website and archived for 90 days afterward.

LEXINGTON, Mass.--(BUSINESS WIRE)-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference 2024. The conference is being conducted in London, England November 19- 21, 2024.

Dr. Brady’s conversation with Kelly Shi, Ph.D., Senior Vice President, Biotechnology Equity Research at Jefferies LLC., is scheduled to begin at 12:30 p.m. GMT Thursday, November 21, 2024. To view the live webcast, log in to the Investors & Media section of the Aldeyra website at https://ir.aldeyra.com. Following the fireside chat, the webcast will be archived for 90 days.

About Aldeyra

Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX-248, ADX-743, ADX-631, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241114786147/en/

Investor & Media Contact:

Laura Nichols

Tel: (781) 257-3060

investorrelations@aldeyra.com

Source: Aldeyra Therapeutics, Inc.

FAQ

When is Aldeyra Therapeutics (ALDX) presenting at the Jefferies London Healthcare Conference 2024?

Aldeyra Therapeutics will present on Thursday, November 21, 2024, at 12:30 p.m. GMT during a fireside chat.

How can investors watch Aldeyra's (ALDX) presentation at the Jefferies Conference?

Investors can watch the live webcast through the Investors & Media section of Aldeyra's website at https://ir.aldeyra.com. The webcast will be archived for 90 days after the event.

Who will represent Aldeyra Therapeutics (ALDX) at the Jefferies London Healthcare Conference 2024?

Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will represent the company in a fireside chat with Kelly Shi from Jefferies.